Skip to content

The Effects of Dietary Fibres on Metabolic Health and the Gut Microbiome

The Modulatory Effects of Dietary Fibres on the Composition and Function of the Gut Microbiome- A Pilot Randomised Placebo-controlled Dietary Intervention Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06580132
Enrollment
19
Registered
2024-08-30
Start date
2021-09-09
Completion date
2022-09-09
Last updated
2024-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diet, Healthy, Systemic Inflammatory Response

Keywords

Dietary intervention, Gut microbiome, Systemic inflammation

Brief summary

The study involves intake of dietary supplements, which are commonly found in the UK diet (not pharmacological agents) to test their effects on inflammation in the body and gut microbiome composition. Study subjects will be healthy volunteers recruited from the University and local population and will be asked to attend the laboratory on 2 occasions; before and after 4-week' supplementing the diet daily with either the dietary fibres (the current trial focussed on pectin) or placebo (maltodextrin). At each study visit (\ 3hrs), participants will be asked to provide a stool and blood sample and will have blood pressure measured. In the week before each study visit, participants will record their food intake.

Detailed description

The overall aim of the proposed project is to unlock the effect of dietary fibres (i.e. LM Pectin) on anti-inflammatory and cardioprotective metabolic responses via the modulation of the gut microbiome and SCFAs production. Specific Aim 1: To deliver a wealth of molecular data, including effect sizes, on the physiological effects of dietary fibres on the changes in the composition and function of the gut microbiome and changes in the metabolomic and physiological profile of an individual. Specific Aim 2: To investigate the mechanisms whereby the gut microbiome modulates crucial physiological parameters such, blood glucose regulation, hunger and appetite, immune function markers in response to the anti-inflammatory effects of the gut microbiome. 30 healthy, non-obese volunteers will be recruited following a successful medical screening. Between recruitment and first study visit, and in the final week of the 4-week intervention (before the second study visit), participants will be asked to complete a dietary record (4 days), to collect a stool sample on the day before the study visit and to fast from midnight the night before this visit. At both study visits, participants will have weight, hip/waist circumference and blood pressure measured. They will be asked to complete some questionnaires. After completion of the first study day, participants will be randomised to receive either the dietary fibre or placebo powder. They will be given the blinded products portioned in individual sachets, with instructions to add the contents of one sachet a day to juice, smoothies or water and to consume immediately. Study visit 2 will be scheduled at the end of the 4 week 'dosing' period.

Interventions

DIETARY_SUPPLEMENTPectin

Pectin fibre (20g) was randomly allocated to eligible participants in order to test specific effects on gut microbiome composition and metabolic markers.

DIETARY_SUPPLEMENTMaltodextrin

Maltodextrin (10g) served as a control/ placebo to compare the effects observed with pectin.

Sponsors

Elizabeth Simpson
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)

Masking description

Single blinded study

Intervention model description

Controlled intervention

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Participant is willing and able to give informed consent for participation in the study * Participant eligibility includes those aged \>18 years who have a body mass index (BMI) between 18.5 and 39.9 kg/m2

Exclusion criteria

The participant may not enter the study if ANY of the following apply: * Have psychosocial or gastrointestinal (e.g. malabsorptive conditions such as IBS/IBD, coeliac) * Are taking the following medications: immunosuppressants, amiodarone and/or perhexiline * Are currently following or anticipated to commence a specialised commercially available weight loss diet and/or program/ taking prebiotic supplements * Pregnant or breastfeeding * History or current psychiatric illness * History or current neurological condition (e.g. epilepsy) * Having taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance.

Design outcomes

Primary

MeasureTime frameDescription
Change in microbiome profile4 weeksChange in microbiome profile, assessed using 16s RNA sequencing analysis of faecal samples provided pre and post the 4-week intervention period
Change in inflammatory profile4 weeksChange in circulating markers of inflammation measured by ELISAs in serum samples collected pre and post the 4-week intervention period.
Changes in short chain fatty acids (SCFAs)4 weeksChange in serum SCFAs measured by mass spectrometry pre and post the 4-week intervention period

Secondary

MeasureTime frameDescription
Change in diastolic blood pressure (lying to standing) post intervention4 minutesChange in diastolic blood pressure (measured after 3 minutes of lying down and after 1 minute of standing), at post-intervention study visit
Change in Short Form Health Survey (SF12) Questionnaire aggregated normalised 'physical' score4 weeksChange in 'SF12' Questionnaire aggregated 'physical' score (normalised to UK population) calculated according to standard procedures (min 0, max 100), with higher score indicating better physical wellbeing; measured pre and post intervention
Change in systolic blood pressure (lying to standing) pre intervention4 minutesChange in systolic blood pressure (measured after 3 minutes of lying down and after 1 minute of standing), at pre-intervention study visit
Change in Pittsburgh Sleep Quality Index (PSQI)4 weeksChange in PSQI score (min score 0, max 21), measured pre and post the 4-week intervention, with higher score indicating poorer sleep quality
Change in Hospital Anxiety and Depression Score (HADS)4 weeksChange in anxiety score (min score 0, max 3 with higher score indicating higher anxiety like symptoms), and depression score (min 3, max 0 with lower the scores indicating higher depression like symptoms) measured pre and post the 4-week intervention.
Change in Short Form Health Survey (SF12) Questionnaire aggregated normalised 'mental' score4 weeksChange in 'SF12' Questionnaire aggregated 'mental' score (normalised to UK population) calculated according to standard procedures (min 0, max 100), with higher score indicating better mental wellbeing; measured pre and post intervention
Change in systolic blood pressure (lying to standing) post intervention4 minutesChange in systolic blood pressure (measured after 3 minutes of lying down and after 1 minute of standing), at post-intervention study visit
Change in diastolic blood pressure (lying to standing) pre intervention4 minutesChange in diastolic blood pressure (measured after 3 minutes of lying down and after 1 minute of standing), at pre-intervention study visit

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026